The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

Work +1 512 457 7000
Fax +1 512 457 7001

Aaron Fountain

Work <div>+1 512 457 7190</div>
DLA Piper LLP (US)

Work Department

Intellectutal Property and Technology; Litigatin, Arbitration and Investigations; Patent Litigation; Patent Prosecution and Strategic Patent Counseling; Technology; Life Sciences




Aaron Fountain concentrates his practice on patent litigation and other intellectual property related matters. Aaron has extensive experience representing clients in dozens of patent infringement matters in the Eastern District of Texas and the District of Delaware.

Aaron has also represented clients before the USPTO, including inter partes review proceedings before the Patent Trial and Appeal Board and providing strategic patent portfolio management advice. 

His clients span a range of technologies, including molecular diagnostics, topical pharmaceuticals, telecom infrastructure, set top boxes, oil field services and all manner of software.


J.D., University of Houston Law Center; B.S., Pepperdine University

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

Co-heads of DLA Piper LLP (US)'s practice, San Diego-based Lisa Haile and Matthew Holian in Boston, specialize in patentability and licensing strategies, and product liability and mass tort, respectively. Recent highlights include obtaining issuance of multiple patents for Aegis Therapeutics’ key product areas and assisting Pfizer and Bristol-Myers Squibb (BMS) with multidistrict and state court litigation concerning alleged defects of the clients’ blockbuster anticoagulant medication Eliquis. New York-based litigator Loren Brown has been acting for Medtronic and Covidien in product liability litigation related to complications allegedly caused by some of Covidien’s implantable hernia mesh products. San Diego’s Larry Nishnick and Austin’s Aaron Fountain are names to note for corporate investment and patent litigation respectively.

[back to top]

Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to